Regeneron Pharmaceuticals (NASDAQ:REGN) SVP Sells $1,585,066.72 in Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares in the company, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $803.17 on Friday. The stock’s 50 day simple moving average is $762.17 and its 200 day simple moving average is $665.05. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The firm has a market cap of $84.41 billion, a P/E ratio of 19.33, a P/E/G ratio of 2.11 and a beta of 0.40. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm’s revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $12.07 earnings per share. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.05%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. CreativeOne Wealth LLC raised its position in shares of Regeneron Pharmaceuticals by 17.9% during the 4th quarter. CreativeOne Wealth LLC now owns 782 shares of the biopharmaceutical company’s stock worth $604,000 after buying an additional 119 shares in the last quarter. Kestra Advisory Services LLC increased its stake in shares of Regeneron Pharmaceuticals by 14.9% during the fourth quarter. Kestra Advisory Services LLC now owns 4,405 shares of the biopharmaceutical company’s stock valued at $3,400,000 after acquiring an additional 571 shares during the period. Transamerica Financial Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 380.0% during the fourth quarter. Transamerica Financial Advisors LLC now owns 48 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 38 shares in the last quarter. Parkside Financial Bank & Trust lifted its position in Regeneron Pharmaceuticals by 70.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 278 shares of the biopharmaceutical company’s stock worth $215,000 after purchasing an additional 115 shares during the period. Finally, 1248 Management LLC bought a new position in Regeneron Pharmaceuticals during the 4th quarter valued at $705,000. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and increased their price target for the stock from $627.00 to $860.00 in a research report on Wednesday, January 7th. Zacks Research lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. HSBC upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 24th. BMO Capital Markets increased their price objective on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a report on Thursday, December 4th. Finally, Cantor Fitzgerald lifted their price objective on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $793.81.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.